Effect of Metformin and Vitamin D Supplementation on Metabolic and Hormonal Profiles in Polycystic Ovary Syndrome Women: A Follow-Up Study
Abstract
Background: Insulin resistance in association with obesity is implicated in the pathogenesis of polycystic ovarian syndrome and its primary characteristic of hyperandrogenism. Metformin at a dose of (1700-2000) mg/day, with and without lifestyle, is associated with a beneficial enhancement in BMI and menstrual cycles. We aimed to determine the role of free testosterone: dihydrotestosterone ratio, and sex hormone binding globulin in the evaluation of the efficacy of metformin and vitamin D in the treatment of polycystic ovary syndrome. Methods: This cross-sectional study included 50 infertile women who were diagnosed with PCOS with an age range of (18-40 years). They were classified into Group I: Twenty-five women treated with metformin 850 mg/twice daily and followed for 8 weeks; Group II: Twenty-five women treated with vitamin D3 50.000 IU/wk for the same period. Serum investigations included measurements of prolactin, 25 hydroxyvitamin D, LH, FSH, free testosterone, DHT and SHBG by ELISA technique. Results: This study revealed that the mean values of BMI, HOMA-IR, prolactin and free testosterone: dihydrotestosterone ratio were significantly improved (by lowering) after treatment with metformin and vitamin D. Moreover, Polycystic Ovary Syndrome women treated with metformin revealed significant negative association between HOMA-IR with SHBG (r= -0.593, p=0.009), also significant positive association between HOMA-IR with BMI (r= 0.631, p=0.003). Conclusion: Serum measurements…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 50 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.